Global Follicle Stimulating Hormone research

Follicle Stimulating Hormone Comprehensive Study by Type (Recombinant FSH, Urinary FSH), Application (Infertility Treatment, Assisted Reproductive Technology), End User (Man, Woman, Child) Players and Region - Global Market Outlook to 2026

Follicle Stimulating Hormone Market by XX Submarkets | Forecast Years 2021-2026  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Follicle Stimulating Hormone Market Scope
Follicle Stimulating Hormone plays a role in sexual development and reproduction in both males and females. Follicle stimulating hormone (or FSH) is one of the gonadotrophic hormones; the other being luteinising hormone (or LH). Both are released by the pituitary gland into the bloodstream. In women, this hormone stimulates the growth of ovarian follicles in the ovary before the release of an egg from one follicle at ovulation.

AttributesDetails
Study Period2017-2026
Base Year2020
UnitValue (USD Million)
Key Companies ProfiledFerring Pharmaceuticals (Switzerland), Techwell (United States), IBSA Dialogue Forum (Switzerland), Merck Serono (Switzerland), Organon (United States), Livzon (China), Livzon Pharmaceutical (China) and MSD (United States)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Ferring Pharmaceuticals (Switzerland), Techwell (United States), IBSA Dialogue Forum (Switzerland), Merck Serono (Switzerland), Organon (United States), Livzon (China), Livzon Pharmaceutical (China) and MSD (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Follicle Stimulating Hormone market by Type , by Application (Infertility Treatment and Assisted Reproductive Technology) and Region with country level break-up.

On the basis of geography, the market of Follicle Stimulating Hormone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2020.

Market Leaders and their expansionary development strategies
On 16th Feb 2021, Simple Pharma acquires Testavan® and Vitaros®, two established men’s health brands, from Ferring. By divesting its rights to Simple Pharma on this transaction, Ferring is able to focus on areas of high unmet need to bring the most value to patients and healthcare professionals.
On 9th August 2021, Merck Specialties Pvt ltd, the healthcare business of Merck in India, launched Pergoveris® Pen for advanced infertility treatment in India. This launch emphasizes the company’s motive of fulfilling unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency.


Influencing Trend:
Ovarian hyper stimulation (COH) is widely used in assisted reproductive techniques (ART), such as in-vitro fertilization and embryo transfer and The most popular and efficient ART is in vitro fertilisation (IVF)

Market Growth Drivers:
Increasing demand for FSH Testing in children’s and Growing Demand for Fertility therapies that work with both a woman's egg and a man's sperm are included.

Challenges:
Side Effects of the Drugs And Stringent Government Regulations and Intense Competition in the Market

Restraints:
Side effects Including severe pain in your lower stomach, little or no urination can hamper the Growth

Opportunities:
Rising Healthcare Expenditure on Follicle Stimulating Hormone and Increase in Number of Follicle Stimulating Hormone Awareness Programs

Key Target Audience
New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Type
  • Recombinant FSH
  • Urinary FSH
By Application
  • Infertility Treatment
  • Assisted Reproductive Technology
By End User
  • Man
  • Woman
  • Child

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing demand for FSH Testing in children’s
      • 3.2.2. Growing Demand for Fertility therapies that work with both a woman's egg and a man's sperm are included.
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of the Drugs And Stringent Government Regulations
      • 3.3.2. Intense Competition in the Market
    • 3.4. Market Trends
      • 3.4.1. Ovarian hyper stimulation (COH) is widely used in assisted reproductive techniques (ART), such as in-vitro fertilization and embryo transfer
      • 3.4.2. The most popular and efficient ART is in vitro fertilisation (IVF)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Follicle Stimulating Hormone, by Type, Application, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Follicle Stimulating Hormone (Value)
      • 5.2.1. Global Follicle Stimulating Hormone by: Type (Value)
        • 5.2.1.1. Recombinant FSH
        • 5.2.1.2. Urinary FSH
      • 5.2.2. Global Follicle Stimulating Hormone by: Application (Value)
        • 5.2.2.1. Infertility Treatment
        • 5.2.2.2. Assisted Reproductive Technology
      • 5.2.3. Global Follicle Stimulating Hormone by: End User (Value)
        • 5.2.3.1. Man
        • 5.2.3.2. Woman
        • 5.2.3.3. Child
      • 5.2.4. Global Follicle Stimulating Hormone Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Follicle Stimulating Hormone (Price)
      • 5.3.1. Global Follicle Stimulating Hormone by: Type (Price)
  • 6. Follicle Stimulating Hormone: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ferring Pharmaceuticals (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Techwell (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. IBSA Dialogue Forum (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck Serono (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Organon (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Livzon (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Livzon Pharmaceutical (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MSD (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Follicle Stimulating Hormone Sale, by Type, Application, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Follicle Stimulating Hormone (Value)
      • 7.2.1. Global Follicle Stimulating Hormone by: Type (Value)
        • 7.2.1.1. Recombinant FSH
        • 7.2.1.2. Urinary FSH
      • 7.2.2. Global Follicle Stimulating Hormone by: Application (Value)
        • 7.2.2.1. Infertility Treatment
        • 7.2.2.2. Assisted Reproductive Technology
      • 7.2.3. Global Follicle Stimulating Hormone by: End User (Value)
        • 7.2.3.1. Man
        • 7.2.3.2. Woman
        • 7.2.3.3. Child
      • 7.2.4. Global Follicle Stimulating Hormone Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Follicle Stimulating Hormone (Price)
      • 7.3.1. Global Follicle Stimulating Hormone by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Follicle Stimulating Hormone: by Type(USD Million)
  • Table 2. Follicle Stimulating Hormone Recombinant FSH , by Region USD Million (2015-2020)
  • Table 3. Follicle Stimulating Hormone Urinary FSH , by Region USD Million (2015-2020)
  • Table 4. Follicle Stimulating Hormone: by Application(USD Million)
  • Table 5. Follicle Stimulating Hormone Infertility Treatment , by Region USD Million (2015-2020)
  • Table 6. Follicle Stimulating Hormone Assisted Reproductive Technology , by Region USD Million (2015-2020)
  • Table 7. Follicle Stimulating Hormone: by End User(USD Million)
  • Table 8. Follicle Stimulating Hormone Man , by Region USD Million (2015-2020)
  • Table 9. Follicle Stimulating Hormone Woman , by Region USD Million (2015-2020)
  • Table 10. Follicle Stimulating Hormone Child , by Region USD Million (2015-2020)
  • Table 11. South America Follicle Stimulating Hormone, by Country USD Million (2015-2020)
  • Table 12. South America Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 13. South America Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 14. South America Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 15. Brazil Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 16. Brazil Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 17. Brazil Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 18. Argentina Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 19. Argentina Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 20. Argentina Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 21. Rest of South America Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 24. Asia Pacific Follicle Stimulating Hormone, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 28. China Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 29. China Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 30. China Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 31. Japan Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 32. Japan Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 33. Japan Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 34. India Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 35. India Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 36. India Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 37. South Korea Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 38. South Korea Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 39. South Korea Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 40. Taiwan Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 41. Taiwan Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 42. Taiwan Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 43. Australia Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 44. Australia Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 45. Australia Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 49. Europe Follicle Stimulating Hormone, by Country USD Million (2015-2020)
  • Table 50. Europe Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 51. Europe Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 52. Europe Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 53. Germany Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 54. Germany Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 55. Germany Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 56. France Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 57. France Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 58. France Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 59. Italy Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 60. Italy Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 61. Italy Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 62. United Kingdom Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 65. Netherlands Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 66. Netherlands Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 67. Netherlands Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 68. Rest of Europe Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 71. MEA Follicle Stimulating Hormone, by Country USD Million (2015-2020)
  • Table 72. MEA Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 73. MEA Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 74. MEA Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 75. Middle East Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 76. Middle East Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 77. Middle East Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 78. Africa Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 79. Africa Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 80. Africa Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 81. North America Follicle Stimulating Hormone, by Country USD Million (2015-2020)
  • Table 82. North America Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 83. North America Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 84. North America Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 85. United States Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 86. United States Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 87. United States Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 88. Canada Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 89. Canada Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 90. Canada Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 91. Mexico Follicle Stimulating Hormone, by Type USD Million (2015-2020)
  • Table 92. Mexico Follicle Stimulating Hormone, by Application USD Million (2015-2020)
  • Table 93. Mexico Follicle Stimulating Hormone, by End User USD Million (2015-2020)
  • Table 94. Follicle Stimulating Hormone: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Follicle Stimulating Hormone: by Type(USD Million)
  • Table 104. Follicle Stimulating Hormone Recombinant FSH , by Region USD Million (2021-2026)
  • Table 105. Follicle Stimulating Hormone Urinary FSH , by Region USD Million (2021-2026)
  • Table 106. Follicle Stimulating Hormone: by Application(USD Million)
  • Table 107. Follicle Stimulating Hormone Infertility Treatment , by Region USD Million (2021-2026)
  • Table 108. Follicle Stimulating Hormone Assisted Reproductive Technology , by Region USD Million (2021-2026)
  • Table 109. Follicle Stimulating Hormone: by End User(USD Million)
  • Table 110. Follicle Stimulating Hormone Man , by Region USD Million (2021-2026)
  • Table 111. Follicle Stimulating Hormone Woman , by Region USD Million (2021-2026)
  • Table 112. Follicle Stimulating Hormone Child , by Region USD Million (2021-2026)
  • Table 113. South America Follicle Stimulating Hormone, by Country USD Million (2021-2026)
  • Table 114. South America Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 115. South America Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 116. South America Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 117. Brazil Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 118. Brazil Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 119. Brazil Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 120. Argentina Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 121. Argentina Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 122. Argentina Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 123. Rest of South America Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 124. Rest of South America Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 125. Rest of South America Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 126. Asia Pacific Follicle Stimulating Hormone, by Country USD Million (2021-2026)
  • Table 127. Asia Pacific Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 128. Asia Pacific Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 129. Asia Pacific Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 130. China Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 131. China Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 132. China Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 133. Japan Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 134. Japan Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 135. Japan Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 136. India Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 137. India Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 138. India Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 139. South Korea Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 140. South Korea Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 141. South Korea Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 142. Taiwan Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 143. Taiwan Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 144. Taiwan Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 145. Australia Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 146. Australia Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 147. Australia Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 148. Rest of Asia-Pacific Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 151. Europe Follicle Stimulating Hormone, by Country USD Million (2021-2026)
  • Table 152. Europe Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 153. Europe Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 154. Europe Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 155. Germany Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 156. Germany Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 157. Germany Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 158. France Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 159. France Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 160. France Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 161. Italy Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 162. Italy Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 163. Italy Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 164. United Kingdom Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 165. United Kingdom Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 166. United Kingdom Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 167. Netherlands Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 168. Netherlands Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 169. Netherlands Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 170. Rest of Europe Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 171. Rest of Europe Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 172. Rest of Europe Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 173. MEA Follicle Stimulating Hormone, by Country USD Million (2021-2026)
  • Table 174. MEA Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 175. MEA Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 176. MEA Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 177. Middle East Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 178. Middle East Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 179. Middle East Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 180. Africa Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 181. Africa Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 182. Africa Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 183. North America Follicle Stimulating Hormone, by Country USD Million (2021-2026)
  • Table 184. North America Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 185. North America Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 186. North America Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 187. United States Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 188. United States Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 189. United States Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 190. Canada Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 191. Canada Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 192. Canada Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 193. Mexico Follicle Stimulating Hormone, by Type USD Million (2021-2026)
  • Table 194. Mexico Follicle Stimulating Hormone, by Application USD Million (2021-2026)
  • Table 195. Mexico Follicle Stimulating Hormone, by End User USD Million (2021-2026)
  • Table 196. Follicle Stimulating Hormone: by Type(USD/Units)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Follicle Stimulating Hormone: by Type USD Million (2015-2020)
  • Figure 5. Global Follicle Stimulating Hormone: by Application USD Million (2015-2020)
  • Figure 6. Global Follicle Stimulating Hormone: by End User USD Million (2015-2020)
  • Figure 7. South America Follicle Stimulating Hormone Share (%), by Country
  • Figure 8. Asia Pacific Follicle Stimulating Hormone Share (%), by Country
  • Figure 9. Europe Follicle Stimulating Hormone Share (%), by Country
  • Figure 10. MEA Follicle Stimulating Hormone Share (%), by Country
  • Figure 11. North America Follicle Stimulating Hormone Share (%), by Country
  • Figure 12. Global Follicle Stimulating Hormone: by Type USD/Units (2015-2020)
  • Figure 13. Global Follicle Stimulating Hormone share by Players 2020 (%)
  • Figure 14. Global Follicle Stimulating Hormone share by Players (Top 3) 2020(%)
  • Figure 15. Global Follicle Stimulating Hormone share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Ferring Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Ferring Pharmaceuticals (Switzerland) Revenue: by Geography 2020
  • Figure 19. Techwell (United States) Revenue, Net Income and Gross profit
  • Figure 20. Techwell (United States) Revenue: by Geography 2020
  • Figure 21. IBSA Dialogue Forum (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. IBSA Dialogue Forum (Switzerland) Revenue: by Geography 2020
  • Figure 23. Merck Serono (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Merck Serono (Switzerland) Revenue: by Geography 2020
  • Figure 25. Organon (United States) Revenue, Net Income and Gross profit
  • Figure 26. Organon (United States) Revenue: by Geography 2020
  • Figure 27. Livzon (China) Revenue, Net Income and Gross profit
  • Figure 28. Livzon (China) Revenue: by Geography 2020
  • Figure 29. Livzon Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 30. Livzon Pharmaceutical (China) Revenue: by Geography 2020
  • Figure 31. MSD (United States) Revenue, Net Income and Gross profit
  • Figure 32. MSD (United States) Revenue: by Geography 2020
  • Figure 33. Global Follicle Stimulating Hormone: by Type USD Million (2021-2026)
  • Figure 34. Global Follicle Stimulating Hormone: by Application USD Million (2021-2026)
  • Figure 35. Global Follicle Stimulating Hormone: by End User USD Million (2021-2026)
  • Figure 36. South America Follicle Stimulating Hormone Share (%), by Country
  • Figure 37. Asia Pacific Follicle Stimulating Hormone Share (%), by Country
  • Figure 38. Europe Follicle Stimulating Hormone Share (%), by Country
  • Figure 39. MEA Follicle Stimulating Hormone Share (%), by Country
  • Figure 40. North America Follicle Stimulating Hormone Share (%), by Country
  • Figure 41. Global Follicle Stimulating Hormone: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Ferring Pharmaceuticals (Switzerland)
  • Techwell (United States)
  • IBSA Dialogue Forum (Switzerland)
  • Merck Serono (Switzerland)
  • Organon (United States)
  • Livzon (China)
  • Livzon Pharmaceutical (China)
  • MSD (United States)
Select User Access Type

Key Highlights of Report


Aug 2022 219 Pages 96 Tables Base Year: 2020 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Follicle Stimulating Hormone research Quantitative research analysis
Global Follicle Stimulating Hormone research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Follicle Stimulating Hormone Market are by type [Recombinant FSH and Urinary FSH], by end use application [Infertility Treatment and Assisted Reproductive Technology].
The Follicle Stimulating Hormone Market is gaining popularity and expected to see strong valuation by 2026.
  • Increasing demand for FSH Testing in children’s
  • Growing Demand for Fertility therapies that work with both a woman's egg and a man's sperm are included.

Know More About Global Follicle Stimulating Hormone research Report?

Have a Query? Click Here

Other Related Reports

Protein Expression Comprehensive Study by Application (Therapeutic, Research, Industrial), Systems Type (Prokaryotic Expression Systems {Escherichia coli (E. coli) Systems and Other Systems}, Mammali...
$ 3750
Regenerative Medicine Comprehensive Study by Type (Cell-Based, Acellular), Application (Cardiovascular, Oncology, Dermatology, Wound Healing, Neurology, Others), Technology (Stem Cell Therapy, Platel...
$ 3450
Glucagon Comprehensive Study by Type (Glucagon Like Peptide 1, Glucagon Like Peptide 2), Application (Hypoglycemia, Radiologic Examination, Cardiogenic Shock, Emergency Kits, Others), End Users (Hosp...
$ 3800
Herceptin Biosimilar Comprehensive Study by Type (Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera), Application (Anti-Arthritis Drugs, Anti-Cancer Drugs, Respiratory Products, Anti-Infective Drugs, C...
$ 3750
Hyaluronic Acid Comprehensive Study by Type (Single-Injection, Three-Injection Cycle, Five-Injection Cycle), Application (Anti-Aging Treatments, Nutritional Supplements, Medical Treatments, Others), ...
$ 3450
Tecentriq Comprehensive Study by Application (Lung Problems, Intestinal Problems, Liver Problems, Hormone Gland Problems, Kidney Problems, Skin Problems, Others), End User (Hospital, Clinic, Others)...
$ 3500